Shield secures Activated Factor XII (AFT) deal
This article was originally published in Clinica
Executive Summary
Shield Diagnostics has strengthened its links with Abbott with the signing of a long-awaited licensing agreement for the UK company's Activated Factor XII heart attack prediction test. Under the worldwide agreement, Shield will develop, manufacture and distribute its assay for use on Abbott's IMx automated instrument. While the terms of the deal are confidential, it is understood there are no upfront payments. Mr Evans said the company is looking for additional partners for a deal on AFT, but he stressed that "those that come later pay a higher price".